Different patterns of p16 immunoreactivity in cervical biopsies: correlation to lesion grade and HPV detection, with a review of the literature

p16 is one extensively studied marker in gynecological pathology. However, its routine application in the diagnosis of squamous intraepithelial lesions of the uterine cervix may present difficulties for the general pathologist. The aim of the present study was to examine a series of 100 cervical biopsies/LEEP specimens, with detailed HPV-typing, for patterns of p16 immunoreactivity and possible correlations with morphology and HPV types. Four patterns of immunopositivity were recognized, according to the distribution of positively stained cells, and these correlated to lesion grade. A review of the pertinent literature concerning p16 immunoreactivity in squamous intraepithelial lesions and nonneoplastic epithelia of the uterine cervix is included in an effort to summarize the existing data and the remaining questions at both the practical and theoretical level.

Cervix; CIN; HPV; Immunohistochemistry; p16; Patterns; Review; SIL

[1] Crum C.P., Abbott D.W., Quade B.J.: “Cervical cancer screening: from the Papanicolaou smear to the vaccine era”. J. Clin. Oncol., 2003, 21 (10 suppl.), 224.

[2] Lee D., Kim H.Z., Jeong K.W., Shim Y.S., Horikawa I., Barrett J. C. et al.: “Human papillomavirus E2 down-regulates the human telomerase reverse transcriptase promoter”. J. Biol. Chem., 2002, 277, 27748.

[3] Duensing S., Duensing A., Crum C.P., Munger K.: “Human papillomavirus type 16 E7 oncoprotein-induced abnormal centrosome synthesis is an early event in the evolving malignant phenotype”. Cancer Res., 2001, 61, 2356.

[4] Snijders P., Steenbergen R., Heideman D., Meijer C.: “HPV-mediated cervical carcinogenesis: concepts and clinical implications”.

J. Pathol., 2006, 208, 152.

[5] Mittal K.: “Utility of proliferation-associated marker MIB-1 in evaluating lesions of the uterine cervix”. Adv. Anat. Pathol., 1999, 6, 177.

[6] Keating J.T., Cviko A., Riethdorf S., Riethdorf L., Quade B.J., Sun D. et al.: “Ki-67, cyclin E, and p16INK4 are complimentary surrogate biomarkers for human papilloma virus-related cervical neoplasia”. Am. J. Surg. Pathol., 2001, 25, 884.

[7] Lorenzato M., Caudroy S., Bronner C., Evrard G., Simon M., Durlach A. et al.: “Cell cycle and/or proliferation markers: what is the best method to discriminate cervical high-grade lesions?”. Hum. Pathol., 2005, 36, 1101.

[8] Kostopoulou E., Samara M., Kollia P., Zacharouli K., Mademtzis I., Daponte A. et al.: “Correlation between cyclin B1 immunostaining in cervical biopsies and HPV detection by PCR”. Appl. Immunohistochem. Mol. Morphol., 2008, Epub Oct 28.

[9] Lukas J., Parry D., Aagaard L., Mann D.J., Bartkova J., Strauss M. et al.: “Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16”. Nature, 1995, 375, 503.

[10] Serrano M.: “The tumor suppressor protein p16INK4a”. Exp. Cell Res., 1997, 237, 7.

[11] Sano T., Oyama T., Kashiwabara K., Fukuda T., Nakajima T.: “Expression status of p16 protein is associated with human papil-lomavirus oncogenic potential in cervical and genital lesions”. Am. J. Pathol., 1998, 153, 1741.

[12] Sano T., Oyama T., Kashiwabara K., Fukuda T., Nakajima T.: “Immunohistochemical overexpression of p16 protein associated with intact retinoblastoma protein expression in cervical cancer and cervical intraepithelial neoplasia”. Pathol. Int., 1998, 48, 580.

[13] Giarrè M., Caldeira S., Malanchi I., Ciccolini F., Leão M.J., Tommasino M.: “Induction of pRb degradation by the human papillomavirus type 16 E7 protein is essential to efficiently overcome p16INK4a-imposed G1 cell cycle arrest”. J. Virol., 2001, 75, 4705.

[14] Nielsen G.P., Stemmer-Rachamimov A.O., Shaw J., Roy J.E., Koh J., Louis D.N.: “Immunohistochemical survey of p16INK4A expression in normal human adult and infant tissues”. Lab. Invest., 1999, 79, 1137.

[15] Ruas M., Peters G.: “The p16INK4a/CDKN2A tumor suppressor and its relatives”. Biochim. Biophys. Acta, 1998, 1378, F115.

[16] Cohen J.A., Geradts J.: “Loss of Rb and MTS1/CDKN2 (p16) expression in human sarcomas”. Hum. Pathol., 1997, 28, 893.

[17] O’Neill C., McCluggage G.: “p16 expression in the female genital tract and its value in diagnosis”. Adv. Anat. Pathol., 2006, 13, 8.

[18] Nakao Y., Yang X., Yokoyama M., Ferenczy A., Tang S.C., Pater M.M. et al.: “Induction of p16 during immortalization by HPV 16 and 18 and not during malignant transformation”. Br. J. Cancer, 1997, 75, 1410.

[19] Andersson S., Hansson B., Norman I., Gaberi V., Mints M., Hjerpe A. et al.: “Expression of E6/E7 mRNA from ‘high risk’ human papillomavirus in relation to CIN grade, viral load and p16INK4a”.Int. J. Oncol., 2006, 29, 705.

[20] Kelley M.J., Otterson G.A., Kaye F.J., Popescu N.C., Johnson

B. E., Dipaolo J.A.: “CDKN2 in HPV-positive and HPV-negative cervical-carcinoma cell lines”. Int. J. Cancer, 1995, 63, 226.

[21] Klaes R., Benner A., Friedrich T., Ridder R., Herrington S., Jenkins D. et al.: “p16INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia”. Am. J. Surg. Pathol., 2002, 26, 1389.

[22] Tsuda H., Hashiguchi Y., Nishimura S., Kawamura N., Inoue T., Yamamoti K.: “Relationship between HPV typing and abnormality of G1 cell cycle regulators in cervical neoplasm”. Gynecol. Oncol., 2003, 91, 476.

[23] Agoff N., Lin P., Morihara J., Mao C., Kiviat N., Koutsky L.: “p16INK4a expression correlates with degree of cervical neoplasia: a comparison with Ki-67 expression and detection of high-risk HPV types”. Mod. Pathol., 2003, 16, 665.

[24] Yoshida T., Fukuda T., Sano T., Kanuma T., Owada N., Nakajima T.: “Usefulness of liquid-based cytology specimens for the immunocytochemical study of p16 expression and human papillo-mavirus testing. A comparative study using simultaneously sam-pled histology materials”. Cancer (Cancer Cytopathol.), 2004, 102, 100.

[25] Wang S.S., Trunk M., Schiffman M., Herrero R., Sherman M., Burk R. et al.: “Validation of p16INK4a as a marker of oncogenichuman papillomavirus infection in cervical biopsies from a population-based cohort in Costa Rica”. Cancer Epidemiol. Biomarkers Prev., 2004, 13, 1355.

[26] Branca M., Ciotti M., Santini D., Di Bonito L., Giorgi C., Benedetto A. et al.: “p16INK4a expression is related to grade of CIN and high-risk human papillomavirus but does not predict virus clearance after conization or disease outcome”. Int. J. Gynecol. Pathol., 2004, 23, 354.

[27] Negri G., Vittadello F., Romano F., Kasal A., Rivasi F., Girlando S. et al.: “p16INK4a expression and progression risk of lowgrade intraepithelial neoplasia of the cervix uteri”. Virchows Arch., 2004, 445, 616.

[28] Tringler B., Gup C., Singh M., Groshong S., Shroyer A., Heinz D. et al.: “Evaluation of p16INK4a and pRb expression in cervical squamous and glandular neoplasia”. Hum. Pathol., 2004, 35, 689.

[29] Volgareva G., Zavalishina L., Andreeva Y., Frank G., Krutikova E., Golovina D. et al.: “Protein p16 as a marker of dysplastic and neoplastic alterations in cervical epithelial cells”. BMC Cancer, 2004, 4, 58.

[30] Guimarães M., Gonçalves M., Soares C., Bettini J., Duarte R., Soares E.: “Immunohistochemical expression of p16INK4a and bcl-2 according to HPV Type and to the progression of cervical squamous intraepithelial lesions”. J. Histochem. Cytochem., 2005, 53, 509.

[31] Murphy N., Ring M., Hefron C.C., King B., Killalea A., Hughes C. et al.: “p16INK4a, CDC6, and MCM5: predictive biomarkers in cervical preinvasive neoplasia and cervical cancer”. J. Clin. Pathol., 2005, 58, 525.

[32] Dray M., Russell P., Dalrymple C., Wallman N., Angus G., Leong A. et al.: “p16INK4a as a complementary marker of high-grade intraepithelial lesions of the uterine cervix. I: Experience with squamous lesions in 189 consecutive cervical biopsies”. Pathology, 2005, 37, 112.

[33] Kalof A.N., Evans M.F., Simmons-Arnold L., Beatty B., Kumarasen C.: “p16INK4a immunoexpression and HPV in situ hybridization signal patterns: potential markers of high-grade cervical intraepithelial neoplasia”. Am. J. Surg. Pathol., 2005, 29, 674.

[34] Qiao X., Bhuiya T., Spitzer M.: “Differentiating high-grade cervical intraepithelial lesion from atrophy in postmenopausal women using Ki-67, cyclin E, and p16 immunohistochemical analysis”. J. Low Genit. Tract. Dis., 2005, 9, 100.

[35] Lin Z.H., Shen X.H., Jin Z., Kim Y., Lee E., Kim H. et al.: “Human papillomavirus genotyping by oligonucleotide microarray and p16INK4a expression in uterine cervical intraepithelial neoplasm and in invasive carcinoma in Korean women”. Pathol. Int., 2005, 55, 491.

[36] Benevolo M., Mottolese M., Marandino F., Vocaturo G., Sindico R., Piperno G. et al.: “Immunohistochemical expression of p16INK4a is predictive of HR-HPV infection in cervical low-grade lesions”. Mod. Pathol., 2006, 19, 384.

[37] Ishikawa M., Fujii T., Saito M., Nindl I., Ono A., Kubushiro K. et al.: “Overexpression of p16INK4a as an indicator for human papillomavirus oncogenic activity in cervical squamous neoplasia”. Int. J. Gynecol. Cancer, 2006, 16, 347.

[38] Yildiz I., Usubutun A., Firat P., Ayhan A., Kucukali T.: “Efficiency of immunohistochemical p16 expression and HPV typing in cervical squamous intraepithelial lesion grading and review of the p16 literature”. Pathol. Res. Pract., 2007, 203, 445.

[39] Hariri J., Oster A.: “The negative predictive value of p16INK4a to assess the outcome of cervical intraepithelial neoplasia 1 in the uterine cervix”. Int. J. Gynecol. Pathol., 2007, 26, 223.

[40] Van Niekerk D., Guillaud M., Matisic J., Benedet J., Freeberg J., Follen M. et al.: “p16 and MIB1 improve the sensitivity and specificity of the diagnosis of high grade squamous intraepithelial lesions: Methodological issues in a report of 447 biopsies with consensus diagnosis and HPV HCII testing”. Gynecol. Oncol., 2007, 107, S233.

[41] Regauer S., Reich O.: “CK17 and p16 expression patterns distinguish (atypical) immature squamous metaplasia from high-grade cervical intraepithelial neoplasia (CIN III)”. Histopathology, 2007, 50, 629.

[42] Iaconis L., Hyjek E., Ellenson L., Pirog E.: “p16 and Ki-67 immunostaining in atypical immature squamous metaplasia of the uterine cervix. Correlation with human papillomavirus detection”. Arch. Pathol. Lab. Med., 2007, 131, 1343.

[43] Kong C., Balzer B., Troxell M., Patterson B., Longacre T.: “p16INK4a immunohistochemistry is superior to HPV in situ hybridization for the detection of high-risk HPV in atypical squamous metaplasia”. Am. J. Surg. Pathol., 2007, 31, 33.

[44] Eleuterio J., Giraldo P., Goncalves A., Cavalcante D., Almeida Ferreira F., Mesquita S. et al.: “Prognostic markers of high-grade squamous intraepithelial lesions: the role of p16INK4a and high-risk human papillomavirus”. Acta Obstet. Gynecol., 2007, 86, 94.

[45] Focchi G., Silva I., Nogueira-de-Souza N., Dobo C., Oshima C., Stavale J.: “Immunohistochemical expression of p16(INK4A) in normal uterine cervix, nonneoplastic epithelial lesions, and lowgrade squamous intraepithelial lesions”. J. Low Genit. Tract. Dis., 2007, 11, 98.

[46] Shi J., Liu H., Wilkerson M., Huang Y., Meschter S., Dupree W., Schuerch C., Lin F.: “Evaluation of p16INK4a, minichromosome maintenance protein 2, DNA topoisomerase IIA, ProEX C, and p16INK4a/ProEX C in cervical squamous intraepithelial lesions”. Hum. Pathol., 2007, 38, 1335.

[47] Redman R., Rufforny I., Liu C., Wilkinson E., Massoll N.: “The utility of p16INK4A in discriminating between cervical intraepithelial neoplasia 1 and nonneoplastic equivocal lesions of the cervix”. Arch. Pathol. Lab. Med., 2008, 132, 795.

[48] Ozgul N., Cil A., Bozdayi G., Usubutun A., Bulbul D., Rota S. et al.: “Staining characteristics of p16INK4a: Is there a correlation with lesion grade or high-risk human papilloma virus positivity?”. J. Obstet. Gynaecol. Res., 2008, 34, 865.

[49] Pinto A., Schlecht N., Woo T., Crum C.P., Cibas E.: “Biomarker (ProExTM C, p16INK4A, and MiB-1) distinction of high-grade squamous intraepithelial lesion from its mimics”. Mod. Pathol., 2008, 21, 1067.

[50] Ordi J., Garcia S., del Pino M., Landol S., Alonso I., Quinto L., Torne A.: “p16INK4a immunostaining identifies occult CIN lesions in HPV-positive women”. Int. J. Gynecol. Pathol., 2008, 28, 90.

[51] Crum C.P., Rose P.: “Cervical squamous neoplasia”. In: Crum C.P., Lee K.R. (eds.). Diagnostic Gynecologic and Obstetric Pathology. Elsevier, 2006, 267.

[52] Kurman R., Norris H., Wilkinson E.: “Tumors of the cervix, vagina and vulva”. In: Rosai J., Sobin L.M. (eds.). Atlas of Tumor Pathology, 3rd series. Washington; DC, AFIP, 1992, 78.

[53] Macaluso M., Montanari M., Cinti C., Giordano A.: “Modulation of cell cycle components by epigenetic and genetic events”. Semin. Oncol., 2005, 32, 452.

[54] Quelle D., Zindy F., Ashmund R., Sherr C.J.: “Alternative reading frames of the INK4 tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest”. Cell, 1995, 83, 993.

[55] Ohtani N., Yamakoshi K., Takahashi A., Hara E.: “The p16INK4A-RB pathway: molecular link between cellular senescence and tumor suppression”. J. Med. Invest., 2004, 51, 146.

[56] Jeong D., Youm M., Kim Y., Lee K., Sung M., Yoon H. et al.: “Promoter methylation of p16, DAPK, CDH1, and TIMP-3 genes in cervical cancer: correlation with clinicopathologic characteristics”. Int. J. Gynecol. Cancer, 2006, 16, 1234.

[57] Borg A., Sandberg T., Nilsson K., Johannsson O., Klinker M., Måsbäck A. et al.: “High frequency of multiple melanomas andbreast and pancreas carcinomas in CDKN2A mutation-positive melanoma families”. J. Natl. Cancer Inst., 2000, 92, 1260.

[58] Dong S., Kim H., Rha S., Sidransky D.: “Promoter Hypermethylation of multiple genes in carcinoma of the uterine cervix”. Clin. Cancer Res., 2001, 7, 1982.

[59] Virmani A., Muller C., Rathi A., Zoechbauer-Mueller S., Mathis M., Gazdar A.: “Aberrant methylation during cervical carcinogenesis”. Clin. Cancer Res., 2001, 7, 584.

[60] Nuovo G., Plaia T., Belinsky S., Baylin S., Herman J.: “In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis”. PNAS, 1999, 96, 12754.

[61] Nakashima R., Fujita M., Enomoto T., Haba T., Yoshino K., Wada H. et al.: “Alteration of p16 and p15 genes in human uterine tumours”. Br. J. Cancer, 1999, 80, 458.

[62] Nehls K., Vinokurova S., Schmidt D., Kommoss F., Reuschenbach M., Kisseljov F. et al.: “p16 methylation does not affect protein expression in cervical carcinogenesis”. Eur. J. Cancer, 2008, 44, 2496.

[63] Munger K., Howley P.: “Human papillomavirus immortalization and transformation functions”. Virus Research, 2002, 89, 213.

[64] Mansour M., Touka M., Malena A., Indiveri C., Dong W., Gionfriddo I. et al.: “Human papillomavirus type 77 E7 protein is a weak deregulator of cell cycle”. Cancer Lett., 2007, 246, 274.

[65] Pett M., Coleman N.: “Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis?”. J. Pathol., 2007, 212, 356.

[66] Terra A., Murta E., Maluf P., Caballero O., Brait M., Adad S.: “Aberrant promoter methylation can be useful as a marker of recurrent disease in patients with cervical intraepithelial neoplasia grade III”. Tumori, 2007, 93, 572.

[67] Horn L., Reichert A., Oster A., Arndal S., Trunk M., Ridder R. et al.: “Immunostaining for p16INK4a used as a conjunctive toolimproves interobserver agreement of the histologic diagnosis of cervical intraepithelial neoplasia”. Am. J. Surg. Pathol., 2008, 32, 502.

[68] Negri G., Bellisano G., Zannoni G.F., Rivasi F., Kasal A., Vittadello F. et al.: “p16ink4a and HPV L1 immunohistochemistry is helpful for estimating the behavior of low-grade dysplastic lesions of the cervix uteri”. Am. J. Surg. Pathol., 2008, 32, 1715.